<DOC>
	<DOC>NCT02869984</DOC>
	<brief_summary>Poor functional outcomes has been reported inevitably, and up to 90% of the patients have experienced bowel habit changes after sphincter-saving surgery for rectal cancer. But, currently there has been no specific treatment for ARS and symptom based empirical management is tried Recently, 5-HT3 receptor antagonists can be used for treatment of IBS-D, and has been revealed to be slowing the bowel movement and improving stool consistency and urgency. We performed the clinical trial with using ramosetron (IrribowÂ®) for the treatment of ARS</brief_summary>
	<brief_title>Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>The patients who undergo sphincter saving surgery for rectal cancer recurred rectal cancer rectal cancer with distant metastasis permanent stoma formation postoperative concurrent chemoradiotherapy uncontrolled medical disease inflammatory bowel disease uncontrolled constipation preoperative incontinence (LARS score, more than 20) allergic to intervention drug</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>